of fiscal 2008 increased 21% over
the second quarter of fiscal 2007 to $87.9 million. Product sales in fiscal
2008 year-to-date increased 20% over fiscal 2007 year-to-date to $166.5
million. These increases reflect continued strong demand from Martek's U.S.
and international infant formula customers, the launch of new and the
growth of existing food and beverage products containing life'sDHA(TM) and
the Company's increased penetration into its other non-infant formula
nutritional markets. Sales to the infant formula market in the second
quarter of fiscal 2008 were approximately $3 million above the high-end of
the guidance previously provided by the Company primarily due to the
production timing and related product ordering patterns of several large
customers.
Following is a breakdown of product sales by market for the second
quarter and year-to-date periods (in thousands):
Three months ended April 30, Six months ended April 30,
%
% incr
2008 2007 incr 2008 2007 (decr)
Infant formula
market $78,390 $65,929 19% $148,668 $126,781 17%
Food and beverage
market 3,172 1,147 177% 5,267 1,868 182%
Pregnancy and
nursing,
nutritional
supplements and
animal feeds 5,113 4,176 22% 10,405 8,149 28%
Non-nutritional
products 1,200 1,084 11% 2,144 2,250 (5%)
Total product
sales $87,875 $72,336 21% $166,484 $139,048 20%
New products launched during the second quarter co-branded with the
Martek life'sDHA(TM) logo include:
Food and Beverage Products
-- Challenge Spreadable Butter with life'sDHA(TM) (
'/>"/>
SOURCE Martek Biosciences Corporation Copyright©2008 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 Related biology technology :1.
Martek to Announce Third Quarter 2007 Results on September 5, 20072.
Martek to Present at Upcoming UBS Conference3.
Martek Signs Multi-Year Worldwide Sole Source Supply Agreement with Abbott4.
Martek Announces Settlement of OmegaTech Milestone Litigation5.
Martek to Obtain Permanent Injunction Against Lonza in U.S. Patent Infringement Suit; Jury Verdict on Infringement of Two of Three Patents Upheld by Judge6.
European Patent Office Upholds Martek European DHA Food Patent; Scope of Original Claims Narrowed7.
Martek to Present at Upcoming ThinkEquity Partners Conference8.
Martek Announces Fourth Quarter and FY 2007 Financial Results9.
Martek Signs DHA/ARA License and Supply Agreement With IlDong Foodis for Infant Formula in South Korea10.
Leading DHA Expert and Former NIH Researcher, Dr. Norman Salem, Jr., to Join Martek as Chief Scientific Officer11.
Challenge Spreadable Butter Now Features Marteks lifesDHA(TM)